Neurofibromatosis Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Conditions:   Neurofibromatosis 1;   Plexiform Neurofibroma;   NF1 Interventions:   Drug: Test group (Group A): FCN-159 8 mg, orally, once daily;;   Drug: Control group (Group B): Placebo, orally, once daily; Sponsor:   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
Condition:   Neurofibromatosis 1 Interventions:   Diagnostic Test: Blood draw;   Other: FACIT-F and Pain Scales Sponsor:   University of Arkansas Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Conditions:   Neurofibromatosis 1;   Plexiform Neurofibroma;   NF1 Interventions:   Drug: Test group (Group A): FCN-159 8 mg, orally, once daily;;   Drug: Control group (Group B): Placebo, orally, once daily; Sponsor:   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
Condition:   Neurofibromatosis 1 Interventions:   Diagnostic Test: Blood draw;   Other: FACIT-F and Pain Scales Sponsor:   University of Arkansas Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Conditions:   Neurofibromatosis 1;   Plexiform Neurofibroma;   NF1 Interventions:   Drug: Test group (Group A): FCN-159 8 mg, orally, once daily;;   Drug: Control group (Group B): Placebo, orally, once daily; Sponsor:   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
Condition:   Neurofibromatosis 1 Interventions:   Diagnostic Test: Blood draw;   Other: FACIT-F and Pain Scales Sponsor:   University of Arkansas Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Conditions:   Neurofibromatosis 1;   Plexiform Neurofibroma;   NF1 Interventions:   Drug: Test group (Group A): FCN-159 8 mg, orally, once daily;;   Drug: Control group (Group B): Placebo, orally, once daily; Sponsor:   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
Condition:   Neurofibromatosis 1 Interventions:   Diagnostic Test: Blood draw;   Other: FACIT-F and Pain Scales Sponsor:   University of Arkansas Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Conditions:   Neurofibromatosis 1;   Plexiform Neurofibroma;   NF1 Interventions:   Drug: Test group (Group A): FCN-159 8 mg, orally, once daily;;   Drug: Control group (Group B): Placebo, orally, once daily; Sponsor:   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
Condition:   Neurofibromatosis 1 Interventions:   Diagnostic Test: Blood draw;   Other: FACIT-F and Pain Scales Sponsor:   University of Arkansas Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Conditions:   Neurofibromatosis 1;   Plexiform Neurofibroma;   NF1 Interventions:   Drug: Test group (Group A): FCN-159 8 mg, orally, once daily;;   Drug: Control group (Group B): Placebo, orally, once daily; Sponsor:   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
Condition:   Neurofibromatosis 1 Interventions:   Diagnostic Test: Blood draw;   Other: FACIT-F and Pain Scales Sponsor:   University of Arkansas Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Conditions:   Neurofibromatosis 1;   Plexiform Neurofibroma;   NF1 Interventions:   Drug: Test group (Group A): FCN-159 8 mg, orally, once daily;;   Drug: Control group (Group B): Placebo, orally, once daily; Sponsor:   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
Condition:   Neurofibromatosis 1 Interventions:   Diagnostic Test: Blood draw;   Other: FACIT-F and Pain Scales Sponsor:   University of Arkansas Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Conditions:   Neurofibromatosis 1;   Plexiform Neurofibroma;   NF1 Interventions:   Drug: Test group (Group A): FCN-159 8 mg, orally, once daily;;   Drug: Control group (Group B): Placebo, orally, once daily; Sponsor:   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials